Cytokinetics CEO Robert I. Blum disposes of 7,500 common shares for $606,525
CYTK•CEO exercises options and sells shares
- Cytokinetics President and CEO Robert I. Blum exercised 7,500 non-qualified stock options at $10.60 on July 27, 2026.
- Blum sold 7,500 shares at $80.87 on the same day.
- Directly held common stock fell to 377,820 shares following the transactions.
